Clinical Trial Update: A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pharmacokinetics and safety of risdiplam in infants with spinal muscular atrophy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Risdiplam (Evrysdi) (risdiplam)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscular Atrophy, Spinal | Phase 2 | Status: RECRUITING